Jim van Heusden
Vorsitzender bei Breye Therapeutics ApS
Ursprung des Netzwerks ersten Grades von Jim van Heusden
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
26
| Public Company | Investment Managers | 26 |
| Public Company | Financial Conglomerates | 11 | |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen.
8
| Private Company | Miscellaneous Commercial Services | 8 |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
5
| Operating Division | Investment Managers | 5 |
Breye Therapeutics ApS
 Breye Therapeutics ApS Pharmaceuticals: MajorHealth Technology Breye Therapeutics ApS is a biopharmaceutical company based in Copenhagen, Denmark. The Danish company develops novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to diabetic retinopathy (DR) or age-related macular degeneration (AMD). Breye Therapeutics' lead program with Danegaptide has a clinically de-risked safety profile and potential for a short and well-accepted clinical regulatory pathway. The company aims to provide less burdensome and more effective treatments for DR and AMD patients, which are currently treated with unpopular intravitreal injections directly into the eye. The company was founded in 2019, and the CEO is Ulrik Mouritzen.
4
| Holding Company | Pharmaceuticals: Major | 4 |
ReWind Therapeutics NV
 ReWind Therapeutics NV Pharmaceuticals: MajorHealth Technology ReWind Therapeutics NV is a biotech company based in Leuven, Belgium that develops first-in-class remyelinating therapies for myelin-related diseases. The Belgian company's aim is to bring these therapies into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged, leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition, and movement, among others. ReWind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis, or nerve injuries. The company's team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics. The company was founded in 2017 by Ku Leuven's Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. The CEO of the company since 2021 is Anja Harmeier.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Gimv Life Sciences
 Gimv Life Sciences Investment ManagersFinance Gimv Life Sciences (Gimv-LS) is the venture capital division of Belgium's Gimv NV (XB: GIMB), an investment firm founded in 1980. Based in Antwerp, Gimv-LS manages a variety of funds which focus on investing in European companies in the life sciences / biotech sector, including the Biotech Fonds Vlaanderen, which was established at the request of the Flemish Region to provide venture capital to existing and start-up medium and large-sized companies in the Flemish biotechnology sector.
1
| Subsidiary | Investment Managers | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Jim van Heusden
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| Ghent University | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree Graduate Degree Corporate Officer/Principal Graduate Degree | |
| Katholieke Universiteit Leuven | College/University | Chairman Graduate Degree Graduate Degree Graduate Degree Graduate Degree Undergraduate Degree | |
Participatiemaatschappij Vlaamse NV
 Participatiemaatschappij Vlaamse NV Investment ManagersFinance Participatiemaatschappij Vlaamse NV (VPM), also known as the Flemish Participation Company, is the investment arm of the Flemish Government based in Brussels, Belgium. Established in 2006, they focus on the management of the Flemish government's minority participation in the GIMV1 fund. GIMV-Gewestelijke Investerings Maatschappij Vlaanderen is a private equity firm founded in 1980 to provide capital to the Flemish industry, primarily in the ICT and life sciences sectors. | Investment Managers | Director/Board Member Director/Board Member President Director/Board Member Director/Board Member Director/Board Member | |
Gimv (Private Equity)
 Gimv (Private Equity) Investment ManagersFinance Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium. | Investment Managers | Private Equity Investor Chief Executive Officer Private Equity Investor Private Equity Analyst Comptroller/Controller/Auditor Director of Finance/CFO | |
| University of Antwerp | College/University | Graduate Degree Undergraduate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree | |
| ABLYNX | Biotechnology | Director/Board Member Chairman Director/Board Member Corporate Officer/Principal | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Corporate Officer/Principal | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| Hogeschool-Universiteit Brussel | College/University | Undergraduate Degree Director/Board Member Undergraduate Degree | |
| Vrije Universiteit Brussel | College/University | Undergraduate Degree Graduate Degree Graduate Degree | |
| University of Copenhagen | College/University | Doctorate Degree Graduate Degree Doctorate Degree | |
| CANTARGIA AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Vlaams Engineering en Testcentrum NV | Chairman Director/Board Member | ||
The Belgian Venture Capital & Private Equity Association
 The Belgian Venture Capital & Private Equity Association Miscellaneous Commercial ServicesCommercial Services The Belgian Venture Capital & Private Equity Association provides equity capital to enterprises not quoted on a stock market. The firm develops new products and technologies to expand working capital, to make acquisitions or to strengthen a company’s balance sheet. The company was founded in 1986 and is headquartered in Brussels, Belgium. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| TIGENIX NV | Medical Specialties | Director/Board Member Founder | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| Voka Vlaams Economisch Verbond VZW | Director/Board Member Director/Board Member | ||
| Vlaamse Raad voor Wetenschapsbeleid | General Government | Chairman Corporate Officer/Principal | |
Caerus Consulting AS
 Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
IWT IST
 IWT IST Miscellaneous Commercial ServicesCommercial Services IWT IST distributes subsidies for projects submitted by small and large businesses, universities, colleges and other Flemish innovative players, either individually or collectively. The foundation was founded in 1991 and is headquartered in Brussels, Belgium. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Smile Invest Management Co. NV
 Smile Invest Management Co. NV Investment ManagersFinance Smile Invest Management Co. NV (Smile Invest) is a private equity firm founded in 2017 by Urbain Vandeurzen. The firm is headquartered in Linden. | Investment Managers | Founder Private Equity Investor | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member Chairman | |
Technopolis NV
 Technopolis NV Media ConglomeratesConsumer Services Technopolis NV provides science and technology services in Flanders. It operates a platform for science and technology in Flanders and has evolved from a non-profit organization, the Flanders Technology International. The company was founded on September 5, 1997 and is headquartered in Mechelen, Belgium. | Media Conglomerates | Director/Board Member Director/Board Member | |
| Vlerick Leuven Gent Management School | College/University | Graduate Degree Corporate Officer/Principal | |
Flanders Technology International
 Flanders Technology International Other Consumer ServicesConsumer Services Flanders Technology International operates historical sites and buildings. The non-profit company is based in Mechelen, Belgium. | Other Consumer Services | Director/Board Member Director/Board Member | |
MyCartis NV
 MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
KBC Securities NV
 KBC Securities NV Investment Banks/BrokersFinance KBC Securities NV is a broker/dealer firm headquartered in Brussels, Belgium. The firm was founded in 1998 and is a wholly owned subsidiary of KBC Bank NV, itself a subsidiary of KBC Groupe SA (EBR: KBC). KBC Securities provides liquidity and order execution services to institutional clients internationally, from investment banks to mutual funds and private investors. | Investment Banks/Brokers | Corporate Officer/Principal Analyst-Equity | |
| BARCO NV | Electronic Equipment/Instruments | Director/Board Member Chairman | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Chief Investment Officer | |
Agoria VZW
 Agoria VZW Miscellaneous Commercial ServicesCommercial Services Agoria VZW is a Belgian company that offers partnership agreements with service providers to provide discounts and benefits to member companies. The private company is based in Brussels, Belgium and was founded in 1946. The company provides expert advice and information on trends and developments tailored to specific sectors or companies. Agoria stimulates cooperation with public stakeholders in sectors such as energy, mobility, buildings, and telecom, and supports initiatives on innovative tendering. The company also supports companies in facing specific challenges in these domains. The CEO is Bart Steukers. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
Federation of Enterprises in Belgium
 Federation of Enterprises in Belgium Miscellaneous Commercial ServicesCommercial Services Federation of Enterprises in Belgium ASBL/VZW fka Federation des Entreprises de Belgique is the only multi-sector employers' organization representing companies in all three regions of Belgium. Its members, Belgium's leading sectoral federations, represent companies in key industrial and service sectors. The company was founded in 1973 and is headquartered in Brussels, Belgium. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Adviesbeheer Gimv Health & Care 2016 NV
 Adviesbeheer Gimv Health & Care 2016 NV Financial ConglomeratesFinance Adviesbeheer Gimv Health & Care 2016 NV is an investment holding Belgian company that provides management, investment, real estate, and public relation services. The company was founded in 2016 and is based in Antwerp, Belgium. | Financial Conglomerates | Director/Board Member Director/Board Member | |
| Université Catholique de Louvain | College/University | Doctorate Degree Graduate Degree | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Chairman | |
deVGen NV
 deVGen NV BiotechnologyHealth Technology deVGen NV provides biotechnology services for the pharmaceutical and agrochemical industries. It innovates in crop protection research and environment induced stress tolerance for its own crops and provides technology to corporate partners. The firm produces and sells its hybrid seeds in field crops such as rice, sunflower, sorghum and pearl millet in the Indian subcontinent and Southeast Asia. The company was founded by Thierry Bogaert on September 10, 1997 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
JenaValve Technology GmbH
 JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Medical Specialties | Director/Board Member Director/Board Member | |
Minoryx Therapeutics SL
 Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Chairman Director/Board Member | |
| BNP PARIBAS FORTIS SA | Major Banks | Director/Board Member Director/Board Member | |
| European Private Equity & Venture Capital Association | Chairman Chairman | ||
| Int'l Private Equity & Venture Capital Valuation Guidelines | Chairman Chairman | ||
| BIOTALYS NV | Chemicals: Agricultural | Director/Board Member Director/Board Member | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services reMYND NV engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders. Its drug and development unit focuses on innovative, disease-modifying drugs for treating degenerative disorders. The company was founded by Fred Van Leuven, Stefaan Wera and Joris Winderickx in 2002 and is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member |
Statistik
International
| Belgien | 31 |
| Schweden | 10 |
| Dänemark | 5 |
| Frankreich | 2 |
| Vereinigte Staaten | 2 |
Sektoral
| Health Technology | 17 |
| Consumer Services | 13 |
| Commercial Services | 9 |
| Finance | 8 |
| Government | 2 |
Operativ
| Director/Board Member | 478 |
| Chairman | 97 |
| Corporate Officer/Principal | 95 |
| Chief Executive Officer | 58 |
| Independent Dir/Board Member | 55 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Gunnar Magnus Modee Persson | 51 |
| Koen Dejonckheere | 46 |
| Francis Vanderhoydonck | 42 |
| Claus Asbjørn Andersson | 41 |
| Viktor Drvota | 41 |
| Bart van Hooland | 38 |
| Bo Jesper Hansen | 34 |
| Khalid Islam | 29 |
| Patrick van Beneden | 28 |
| Herman Daems | 25 |
| Karl Härfstrand | 23 |
| Dirk Boogmans | 22 |
| Carl Johan Bertil Sundberg | 21 |
| Henrijette Richter | 21 |
| Terje Kalland | 20 |
- Börse
- Insiders
- Jim van Heusden
- Unternehmensverbindungen
